Lung Surfactant Accelerates Skin Wound Healing: A Translational Study with a Randomized Clinical Phase I Study

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Autoren

  • Ursula Mirastschijski
  • Igor Schwab
  • Vincent Coger
  • Ulrich Zier
  • Carmela Rianna
  • Wei He
  • Kathrin Maedler
  • Sørge Kelm
  • Arlo Radtke
  • Gazanfer Belge
  • Patrick Lindner
  • Frank Stahl
  • Martin Scharpenberg
  • Lukas Lasota
  • Jürgen Timm

Organisationseinheiten

Externe Organisationen

  • Constructor University Bremen
  • Klinikum Bremen-Mitte
  • Medizinische Hochschule Hannover (MHH)
Forschungs-netzwerk anzeigen

Details

OriginalspracheEnglisch
Aufsatznummer2581
FachzeitschriftScientific reports
Jahrgang10
Ausgabenummer1
PublikationsstatusVeröffentlicht - 13 Feb. 2020

Abstract

Lung surfactants are used for reducing alveolar surface tension in preterm infants to ease breathing. Phospholipid films with surfactant proteins regulate the activity of alveolar macrophages and reduce inflammation. Aberrant skin wound healing is characterized by persistent inflammation. The aim of the study was to investigate if lung surfactant can promote wound healing. Preclinical wound models, e.g. cell scratch assays and full-thickness excisional wounds in mice, and a randomized, phase I clinical trial in healthy human volunteers using a suction blister model were used to study the effect of the commercially available bovine lung surfactant on skin wound repair. Lung surfactant increased migration of keratinocytes in a concentration-dependent manner with no effect on fibroblasts. Significantly reduced expression levels were found for pro-inflammatory and pro-fibrotic genes in murine wounds. Because of these beneficial effects in preclinical experiments, a clinical phase I study was initiated to monitor safety and tolerability of surfactant when applied topically onto human wounds and normal skin. No adverse effects were observed. Subepidermal wounds healed significantly faster with surfactant compared to control. Our study provides lung surfactant as a strong candidate for innovative treatment of chronic skin wounds and as additive for treatment of burn wounds to reduce inflammation and prevent excessive scarring.

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

Lung Surfactant Accelerates Skin Wound Healing: A Translational Study with a Randomized Clinical Phase I Study. / Mirastschijski, Ursula; Schwab, Igor; Coger, Vincent et al.
in: Scientific reports, Jahrgang 10, Nr. 1, 2581, 13.02.2020.

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Mirastschijski, U, Schwab, I, Coger, V, Zier, U, Rianna, C, He, W, Maedler, K, Kelm, S, Radtke, A, Belge, G, Lindner, P, Stahl, F, Scharpenberg, M, Lasota, L & Timm, J 2020, 'Lung Surfactant Accelerates Skin Wound Healing: A Translational Study with a Randomized Clinical Phase I Study', Scientific reports, Jg. 10, Nr. 1, 2581. https://doi.org/10.1038/s41598-020-59394-5
Mirastschijski, U., Schwab, I., Coger, V., Zier, U., Rianna, C., He, W., Maedler, K., Kelm, S., Radtke, A., Belge, G., Lindner, P., Stahl, F., Scharpenberg, M., Lasota, L., & Timm, J. (2020). Lung Surfactant Accelerates Skin Wound Healing: A Translational Study with a Randomized Clinical Phase I Study. Scientific reports, 10(1), Artikel 2581. https://doi.org/10.1038/s41598-020-59394-5
Mirastschijski U, Schwab I, Coger V, Zier U, Rianna C, He W et al. Lung Surfactant Accelerates Skin Wound Healing: A Translational Study with a Randomized Clinical Phase I Study. Scientific reports. 2020 Feb 13;10(1):2581. doi: 10.1038/s41598-020-59394-5
Mirastschijski, Ursula ; Schwab, Igor ; Coger, Vincent et al. / Lung Surfactant Accelerates Skin Wound Healing : A Translational Study with a Randomized Clinical Phase I Study. in: Scientific reports. 2020 ; Jahrgang 10, Nr. 1.
Download
@article{f444ebe9b1a8421d961b8ea0b43afe6f,
title = "Lung Surfactant Accelerates Skin Wound Healing: A Translational Study with a Randomized Clinical Phase I Study",
abstract = "Lung surfactants are used for reducing alveolar surface tension in preterm infants to ease breathing. Phospholipid films with surfactant proteins regulate the activity of alveolar macrophages and reduce inflammation. Aberrant skin wound healing is characterized by persistent inflammation. The aim of the study was to investigate if lung surfactant can promote wound healing. Preclinical wound models, e.g. cell scratch assays and full-thickness excisional wounds in mice, and a randomized, phase I clinical trial in healthy human volunteers using a suction blister model were used to study the effect of the commercially available bovine lung surfactant on skin wound repair. Lung surfactant increased migration of keratinocytes in a concentration-dependent manner with no effect on fibroblasts. Significantly reduced expression levels were found for pro-inflammatory and pro-fibrotic genes in murine wounds. Because of these beneficial effects in preclinical experiments, a clinical phase I study was initiated to monitor safety and tolerability of surfactant when applied topically onto human wounds and normal skin. No adverse effects were observed. Subepidermal wounds healed significantly faster with surfactant compared to control. Our study provides lung surfactant as a strong candidate for innovative treatment of chronic skin wounds and as additive for treatment of burn wounds to reduce inflammation and prevent excessive scarring.",
keywords = "Animals, Blister/drug therapy, Cell Proliferation/drug effects, Cicatrix/drug therapy, Female, Fibroblasts/drug effects, Humans, Inflammation/drug therapy, Keratinocytes/drug effects, Mice, Pulmonary Surfactant-Associated Proteins/pharmacology, Skin/drug effects, Surface-Active Agents, Wound Healing/drug effects",
author = "Ursula Mirastschijski and Igor Schwab and Vincent Coger and Ulrich Zier and Carmela Rianna and Wei He and Kathrin Maedler and S{\o}rge Kelm and Arlo Radtke and Gazanfer Belge and Patrick Lindner and Frank Stahl and Martin Scharpenberg and Lukas Lasota and J{\"u}rgen Timm",
note = "Funding information: We acknowledge Reinhild Schnabel, Angela F{\"u}lbier, Regina Bolte, Petra Berger and Katrischa Hennekens for excellent technical assistance. We are grateful to K. Junker (Department of Pathology), and C. Lorenz (Department of Pediatric Surgery, both Klinikum Bremen-Mitte, Bremen) for their support and cooperation in this study, to M. Klouche (Bremen Center for Laboratory Medicine GmbH) for performing the blood sample analyses and to Melanie Braun (Blutspendedienst Hamburg) for providing the buffy coats from anonymous funded by the European Research Council under the European Communihealthy donors. We thank Lyomark Pharma GmbH for donating Alveofact{\textregistered}ty{\textquoteright}s Seventh Framework Programmefor the clinical study. This work was (FP7/2007-2013; n° 243195) and under the European Union{\textquoteright}s Horizon 2020 research and innovation programme (No. 693017).",
year = "2020",
month = feb,
day = "13",
doi = "10.1038/s41598-020-59394-5",
language = "English",
volume = "10",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Download

TY - JOUR

T1 - Lung Surfactant Accelerates Skin Wound Healing

T2 - A Translational Study with a Randomized Clinical Phase I Study

AU - Mirastschijski, Ursula

AU - Schwab, Igor

AU - Coger, Vincent

AU - Zier, Ulrich

AU - Rianna, Carmela

AU - He, Wei

AU - Maedler, Kathrin

AU - Kelm, Sørge

AU - Radtke, Arlo

AU - Belge, Gazanfer

AU - Lindner, Patrick

AU - Stahl, Frank

AU - Scharpenberg, Martin

AU - Lasota, Lukas

AU - Timm, Jürgen

N1 - Funding information: We acknowledge Reinhild Schnabel, Angela Fülbier, Regina Bolte, Petra Berger and Katrischa Hennekens for excellent technical assistance. We are grateful to K. Junker (Department of Pathology), and C. Lorenz (Department of Pediatric Surgery, both Klinikum Bremen-Mitte, Bremen) for their support and cooperation in this study, to M. Klouche (Bremen Center for Laboratory Medicine GmbH) for performing the blood sample analyses and to Melanie Braun (Blutspendedienst Hamburg) for providing the buffy coats from anonymous funded by the European Research Council under the European Communihealthy donors. We thank Lyomark Pharma GmbH for donating Alveofact®ty’s Seventh Framework Programmefor the clinical study. This work was (FP7/2007-2013; n° 243195) and under the European Union’s Horizon 2020 research and innovation programme (No. 693017).

PY - 2020/2/13

Y1 - 2020/2/13

N2 - Lung surfactants are used for reducing alveolar surface tension in preterm infants to ease breathing. Phospholipid films with surfactant proteins regulate the activity of alveolar macrophages and reduce inflammation. Aberrant skin wound healing is characterized by persistent inflammation. The aim of the study was to investigate if lung surfactant can promote wound healing. Preclinical wound models, e.g. cell scratch assays and full-thickness excisional wounds in mice, and a randomized, phase I clinical trial in healthy human volunteers using a suction blister model were used to study the effect of the commercially available bovine lung surfactant on skin wound repair. Lung surfactant increased migration of keratinocytes in a concentration-dependent manner with no effect on fibroblasts. Significantly reduced expression levels were found for pro-inflammatory and pro-fibrotic genes in murine wounds. Because of these beneficial effects in preclinical experiments, a clinical phase I study was initiated to monitor safety and tolerability of surfactant when applied topically onto human wounds and normal skin. No adverse effects were observed. Subepidermal wounds healed significantly faster with surfactant compared to control. Our study provides lung surfactant as a strong candidate for innovative treatment of chronic skin wounds and as additive for treatment of burn wounds to reduce inflammation and prevent excessive scarring.

AB - Lung surfactants are used for reducing alveolar surface tension in preterm infants to ease breathing. Phospholipid films with surfactant proteins regulate the activity of alveolar macrophages and reduce inflammation. Aberrant skin wound healing is characterized by persistent inflammation. The aim of the study was to investigate if lung surfactant can promote wound healing. Preclinical wound models, e.g. cell scratch assays and full-thickness excisional wounds in mice, and a randomized, phase I clinical trial in healthy human volunteers using a suction blister model were used to study the effect of the commercially available bovine lung surfactant on skin wound repair. Lung surfactant increased migration of keratinocytes in a concentration-dependent manner with no effect on fibroblasts. Significantly reduced expression levels were found for pro-inflammatory and pro-fibrotic genes in murine wounds. Because of these beneficial effects in preclinical experiments, a clinical phase I study was initiated to monitor safety and tolerability of surfactant when applied topically onto human wounds and normal skin. No adverse effects were observed. Subepidermal wounds healed significantly faster with surfactant compared to control. Our study provides lung surfactant as a strong candidate for innovative treatment of chronic skin wounds and as additive for treatment of burn wounds to reduce inflammation and prevent excessive scarring.

KW - Animals

KW - Blister/drug therapy

KW - Cell Proliferation/drug effects

KW - Cicatrix/drug therapy

KW - Female

KW - Fibroblasts/drug effects

KW - Humans

KW - Inflammation/drug therapy

KW - Keratinocytes/drug effects

KW - Mice

KW - Pulmonary Surfactant-Associated Proteins/pharmacology

KW - Skin/drug effects

KW - Surface-Active Agents

KW - Wound Healing/drug effects

UR - http://www.scopus.com/inward/record.url?scp=85079338726&partnerID=8YFLogxK

U2 - 10.1038/s41598-020-59394-5

DO - 10.1038/s41598-020-59394-5

M3 - Article

C2 - 32054903

VL - 10

JO - Scientific reports

JF - Scientific reports

SN - 2045-2322

IS - 1

M1 - 2581

ER -

Von denselben Autoren